0.05 and P values in later four groups were

Objective:To study the clinical pathologic,immunophenotypic and clinical and molecular biological characteristics of subcutaneous panniculitic T-cell lymphoma.Methods:The clinical and pathologic features were studied by clinical observation,laboratory test and clinical pathology.Immunophenotypic features were measured by paraffinnimmunoperoxidase with the antibodies of LCA?CD3?UCHL?L26,by freeze section immunoperoxidase with the antibodies of ??TCR???TCR and analysis of the subtype with the antibodies of V 1 ??V 2 ?.T cell receptor-? gene rearrangements were studied by polymerase chain reaction(PCR).Results:Cutaneous node,high fever,loss of body weight appeared in seven patients and hemophagocytic syndrome in five patients.Imbalance of dielectric,acid and basic,abnormality of the enzyme involvement of the subcutaneous fat in a lacelike pattern with neoplastic cells were seen in all patients.The expression of LCA?CD 3?UCHL occurred in all patients,but no L26.The expression of ??TCR was found in three patients whose ??TCR was V 2+ ? and the expression of ??TCR was found in one of four patients.T cell receptor-? gene rearrangements were seen in three patients.Conclusion:SPTCL is a critical disease.The tumor cells origin from V 2+ ? of T-lymphocyte relating to cutaneous lymphotissue.T cell receptor-? gene rearrangements may happened in SPTCL patient.

Purpose:To study the efficacy and toxicity of VIDM regimen (vincristine,idarubicin,dexamethasone and melphalan) for refractory or relapsed multiple myeloma(MM).Methods:45 refractory or relapsed MM patients were randomized into two groups: VIDM group(treatment group) had 22 patients treated with VIDM regimen, VAD group(control group) had 23 patients with VAD regimen.Results:The effective rate with VIDM regimen (59.1%) was significantly higher than that of VAD regimen (26.1%) (P

Objective:To investigate the expression of adhesion molecule including CD11a、CD11b、CD62L on malignant lymophoproliferative disorders and its clinical implications.Methods:Adhesion molecule CD11a、CD11b、CD62L of 35 Acute Lymophocytic Leukemia(ALL)、30 multiple myeloma(MM)、4 Chronic Lymophocytic Leukemia(CLL)、14 lymphosarocoma cell leukemia patients and 25 health people were measured by flow cytometric analysis.Results:①CD11a and CD11b expression were lower on ALL、MM、CLL cells than the normal hematopoietic cells.CD62L expression were lower on CLL、MM、lymphosarocoma cell leukemic cells than the normal hematopoietic cells.②The CD11a was lower expressed on ALL than lymphosarocoma cell leukemic cells,CD62L was higher on ALL than lymphosarocoma cells leukemia.③The expression of CD11a in the ALL invasion group was much higher than that in the noninvasive group(P

Objective:To study whether the mobilization process is associated with change in expression of adhesion molecules on CD34 +cells Methods:Two colour fluorescence analysis was used to study the expression of adhesion molecule CD62L,CD49d,CD11a,CD11b on CD34 + cells of peripheral blood stem cells(PBSC) before and after mobilizing with G CSF and cytotoxic chemotherapy in 15 cancer patients undergoing PBCST Results:① The expression of adhesion molecules on CD34 +cells revealed a significant reduction of CD11a, CD49d and CD62L at days 7 compared to the baseline level (P

Objective:To study the influence and mechanism of thalidomide on bone marrow hematopoietic progenitor cells in multiple myeloma patients and in normal controls.Methods:Bone marrow GM CFU, E CFU and MK CFU from multiple myeloma patients and from normal controls were cultured in methylcellulose semisolid medium in vitro after being treated by different concentration of thalidomide. IFN ? and TNF ? concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients and from normal controls were measured by ELISA.Results:Thalidomide inhibited GM CFU in multiple myeloma patients and in normal controls at concentration higher than 200 and 100 ?g/ml, respectively, and inhibited MK CFU in multiple myeloma patients and in normal controls at concentration higher than 300 ?g/ml and 150 ?g/ml, respectively. However, there was no significantly influence of thalidomide on E CFU in multiple myeloma patients and in normal controls at concentration between 10 and 400 ?g/ml. Thalidomide increased IFN ? concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients and from normal controls at concentration greater than 100 and 200 ?g/ml, respectively. The level of thalidomide of higher than 300 ?g/ml reduced TNF ? concentration in cell suspension of bone marrow hematopoietic progenitor cells from multiple myeloma patients.Conclusion:Different concentrations of thalidomide have different influences on the hematopoietic function of bone marrow hematopoietic progenitor cells in multiple myeloma patients and in normal controls, probably mediated through increased IFN ? by thalidomide.

Objective:To investigate influence of Fludarabine to lupus activity of lupus mice and the effectiveness and safety of Fludarabine on the treatment of BXSB lupus mice and their possible methanism Methods:Fludarabine of 30 mg/(m 2?d) was injected into BXSB by tail vein,3 days continuously Results of treatment was observed through counting number of peripheral blood WBC Anti ds DNA and anti nuclear antibody in BXSB serum was measured by ELISA Pathologic transformation of kidney or urine protein was measured by immunofluorescence or urine protein test paper after treated by Fludarabine Expression of CD4 +Fas +?CD8 +Fas +?CD45RO + Fas + on T lymphocyte were measured by flowcytometry Results:The number of peripheral blood WBC of BXSB mice began to decline from the third day after treated by Fludarabine The lowest value 〔0 5?0 2)?10 9 L -1 〕of the number of peripheral blood WBC appeared on the seventh day and on the nineteenth day the number of peripheral blood WBC was up to 1 0?10 9 L -1 after treated by Fludarabine The falling of anti ds DNA and anti nuclear antibody in BXSB serum appeared on the fourteenth and twentieth one day after treated by Fludarabine, respectively Reduction of from +～++ turning?kindey immunofluorescence were 72 7% in group of Fludarabine Reduction of protein urine from ++～+++ turning ?～ - appeared on the twentieth one and twentieth eight days Reduction of expression of CD4 +Fas +?CD8 +Fas +?CD45RO + Fas + on T lymphocyte was obvious after treated by Fludarabine Conclusion:Fludarabine can evidently reduce the serum level of anti ds DNA and anti nuclear antibody of BXSB and reduce injury of kidney and formation of protein urine So Fludarabine may have good curative effect to severe SLE Fludarabine can reduce expression of CD4 +Fas +?CD8 +Fas +?CD45RO + Fas + on T lymphocyte,which may be one of methanism of Fludarabine to SLE

AIM and METHODS: To investigate the expression of adhesion molecule β2 integrins (CD11a、 CD11b) and L-selectin(CD62L )on Acute Lymophocyte Leukemia(ALL) cells and its Clinical Implications. Adhesion molecules CD11a、CD11b、 CD62L of 45 ALL patients and 25 health people were measured by flow - cytometric analysis. RESULTS :①CD11a and CD11b expression were lower on ALL cells than the normal hematopoietic cells. The rate of low expression was 100% for CD11b, 50% for CD11a,respectively. CD62L expression were higher on ALL cells than the normal hematopoietic cells.②The CD11a was lower expressed on B - ALL than T- ALL. CD62L was higher on T- ALL than B- ALL. ③The expression of CD11a in the invasion group was much higher than that in the non - invasive group( P < 0.05).④The levels of CD11a,CD11b were returned to normal levels at remission. CONCLUSION: These results suggest that there are abnormalities in the expression of cell adhesion molecules in ALL which may help identify ALL subtypes and the treatment effect.

AIM: Through detecting bone marrow angiogenic mediators and inhibitors in aplastic anemia(AA) patients,the value of angionesis in AA pathogenesis was elucidated.METHODS: The patients were divided into severe AA group(SAA,8 patients),non severe AA group(NSAA,10 patients),and normal control group(7 persons),5 patients were observed before treating(group beginning) and getting improvement(group improving).The angiogenic mediators vascular endothelial growth factor(VEGF) and bFGF were detected by ELISA,angiogenic inhibitors IFN? and TSP were detected by ELISA and flow cytometry,respectively.RESULTS: The levels of VEGF were lower in SAA group and NSAA group than those in control group significantly(P

AIM and METHODS: To investigate the expression of adhesion molecule ? 2 integrins (CD11a、CD11b) and L-selectin(CD62L )on Acute Lymophocyte Leukemia(ALL) cells and its Clinical Implications. Adhesion molecules CD11a、CD11b、 CD62L of 45 ALL patients and 25 health people were measured by flow-cytometric analysis. RESULTS:①CD11a and CD11b expression were lower on ALL cells than the normal hematopoietic cells. The rate of low expression was 100% for CD11b, 50% for CD11a,respectively. CD62L expression were higher on ALL cells than the normal hematopoietic cells.②The CD11a was lower expressed on B-ALL than T-ALL. CD62L was higher on T-ALL than B-ALL. ③ The expression of CD11a in the invasion group was much higher than that in the non-invasive group(P